oatp造句

• SLCO4C1 belongs to the organic anion transporter ( OATP ) family.
• Alignment also includes a single domain from transporters in the OATP / PGT family.
• Also, canertinib is not an inhibitor of OATP-1B1 or OATP-1B3 transporter.
• Also, canertinib is not an inhibitor of OATP-1B1 or OATP-1B3 transporter.
• Many modulators of OATP function have been identified based on in vitro research in OATP-transfected cell lines.
• Many modulators of OATP function have been identified based on in vitro research in OATP-transfected cell lines.
• Both OATP activation and inhibition has been observed and an in silico model for structure-based identification of OATP modulation was developed.
• Both OATP activation and inhibition has been observed and an in silico model for structure-based identification of OATP modulation was developed.
• Also, anti-cancer drugs specially the tyrosine kinase inhibitors have been reported as inhibitors of OATP ( OATP-1B1 and OATP-1B3.
• Also, anti-cancer drugs specially the tyrosine kinase inhibitors have been reported as inhibitors of OATP ( OATP-1B1 and OATP-1B3.
• Also, anti-cancer drugs specially the tyrosine kinase inhibitors have been reported as inhibitors of OATP ( OATP-1B1 and OATP-1B3.
• This interaction is due to the known effect of grapefruit flavonoids on intestinal transporter systems such as P-glycoproteins and organic anion transporting peptide ( OATP ).
• Various anti-cancer drugs like pazopanib, vandetanib, nilotinib, canertinib and erlotinib are known to be transported via OATPs ( OATP-1B1 and OATP-1B3 ).
• Various anti-cancer drugs like pazopanib, vandetanib, nilotinib, canertinib and erlotinib are known to be transported via OATPs ( OATP-1B1 and OATP-1B3 ).
• An "'organic anion-transporting polypeptide "'( OATP ) is a membrane transport protein or'transporter'that mediates the transport of mainly organic anions across the cell membrane.
• Pazopanib and Nilotinib have shown their inhibitory potential only towards OATP-1B1 but not towards OATP-1B3 whereas Vandetanib has shown its inhibitory activity only towards OATP-1B3 but not towards OATP-1B1.
• Pazopanib and Nilotinib have shown their inhibitory potential only towards OATP-1B1 but not towards OATP-1B3 whereas Vandetanib has shown its inhibitory activity only towards OATP-1B3 but not towards OATP-1B1.
• Pazopanib and Nilotinib have shown their inhibitory potential only towards OATP-1B1 but not towards OATP-1B3 whereas Vandetanib has shown its inhibitory activity only towards OATP-1B3 but not towards OATP-1B1.
• Pazopanib and Nilotinib have shown their inhibitory potential only towards OATP-1B1 but not towards OATP-1B3 whereas Vandetanib has shown its inhibitory activity only towards OATP-1B3 but not towards OATP-1B1.